In March 11 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Viveve Medical Inc. (VIVE:NASDAQ) finished enrollment for the VIVEVE II trial of 250 patients across 19 clinical locations in the U.S. and Canada, thereby continuing to advance its clinical programs.
This is the second study for which the biotech completed enrollment this year. The other one, in January, was the LIBERATE-International trial.
"We believe the company has made strong clinical progress and anticipate VIVEVE II data to be released during H1/20," he commented.
VIVEVE II, a randomized, double-blinded study, aims to evaluate the safety and efficacy of cryogen-cooled monopolar radiofrequency technology in improving sexual function in women after having given birth vaginally. There are two primary endpoints. One is safety. The other is the mean change from baseline with respect to the female sexual function index (FSFI). Secondary endpoints include improvements in FSFI scores on desire, arousal, lubrication, satisfaction and pain.
Ladenburg Thalmann has a Buy rating and a $4 target price on Viveve, whose stock is currently trading at around $0.87 per share.[NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Viveve Medical, a company mentioned in this article.
Disclosures from Ladenburg Thalmann, Viveve Medical Inc., March 11, 2019
ANALYST CERTIFICATION: I, Jeffrey S. Cohen, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:
The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm’s total revenues, a portion of which is generated by investment banking activities.
COMPANY SPECIFIC DISCLOSURES:
Ladenburg Thalmann & Co. Inc. makes a market in Viveve Medical, Inc.
Ladenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Viveve Medical, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc received compensation for investment banking services from Viveve Medical, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc had an investment banking relationship with Viveve Medical, Inc. within the last 12 months.